TY - JOUR
T1 - Enhanced resistance to herpes simplex virus type 1 infection in transgenic mice expressing a soluble form of herpesvirus entry mediator
AU - Ono, Etsuro
AU - Yoshino, Saori
AU - Amagai, Keiko
AU - Taharaguchi, Satoshi
AU - Kimura, Chiemi
AU - Morimoto, Junko
AU - Inobe, Manabu
AU - Uenishi, Tomoko
AU - Uede, Toshimitsu
N1 - Funding Information:
This work was supported by Grant-in-Aid for Scientific Research (B)(2) from The Ministry of Education, Culture, Sports, Science and Technology, Japan. We thank Dr. T. Suzutani for HSV-1 strain VR-3 and Dr. J. Arthur for pSLAT2.
PY - 2004/3/15
Y1 - 2004/3/15
N2 - Herpesvirus entry mediator (HVEM) is a member of the tumor necrosis factor (TNF) receptor family used as a cellular receptor by virion glycoprotein D (gD) of herpes simplex virus (HSV). Both human and mouse forms of HVEM can mediate entry of HSV-1 but have no entry activity for pseudorabies virus (PRV). To assess the antiviral potential of HVEM in vivo, three transgenic mouse lines expressing a soluble form of HVEM (HVEMIg) consisting of an extracellular domain of murine HVEM and the Fc portion of human IgG1 were generated. All of the transgenic mouse lines showed marked resistance to HSV-1 infection when the mice were challenged intraperitoneally with HSV-1, but not to PRV infection. The present results demonstrate that HVEMIg is able to exert a significant antiviral effect against HSV-1 infection in vivo.
AB - Herpesvirus entry mediator (HVEM) is a member of the tumor necrosis factor (TNF) receptor family used as a cellular receptor by virion glycoprotein D (gD) of herpes simplex virus (HSV). Both human and mouse forms of HVEM can mediate entry of HSV-1 but have no entry activity for pseudorabies virus (PRV). To assess the antiviral potential of HVEM in vivo, three transgenic mouse lines expressing a soluble form of HVEM (HVEMIg) consisting of an extracellular domain of murine HVEM and the Fc portion of human IgG1 were generated. All of the transgenic mouse lines showed marked resistance to HSV-1 infection when the mice were challenged intraperitoneally with HSV-1, but not to PRV infection. The present results demonstrate that HVEMIg is able to exert a significant antiviral effect against HSV-1 infection in vivo.
UR - http://www.scopus.com/inward/record.url?scp=1542315570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1542315570&partnerID=8YFLogxK
U2 - 10.1016/j.virol.2003.11.031
DO - 10.1016/j.virol.2003.11.031
M3 - Article
C2 - 15016549
AN - SCOPUS:1542315570
SN - 0042-6822
VL - 320
SP - 267
EP - 275
JO - Virology
JF - Virology
IS - 2
ER -